Details for Patent: 7,601,740
✉ Email this page to a colleague
Which drugs does patent 7,601,740 protect, and when does it expire?
Patent 7,601,740 protects NUPLAZID and is included in two NDAs.
Protection for NUPLAZID has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-five patent family members in twenty-one countries.
Summary for Patent: 7,601,740
| Title: | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
| Abstract: | Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis. |
| Inventor(s): | David M. Weiner, Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam |
| Assignee: | Acadia Pharmaceuticals Inc |
| Application Number: | US10/759,561 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,601,740 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Dosage form; |
Drugs Protected by US Patent 7,601,740
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acadia Pharms Inc | NUPLAZID | pimavanserin tartrate | CAPSULE;ORAL | 210793-001 | Jun 28, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Acadia Pharms Inc | NUPLAZID | pimavanserin tartrate | TABLET;ORAL | 207318-002 | Jun 28, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Acadia Pharms Inc | NUPLAZID | pimavanserin tartrate | TABLET;ORAL | 207318-001 | Apr 29, 2016 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,601,740
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 407117 | ⤷ Start Trial | |||
| Austria | 512136 | ⤷ Start Trial | |||
| Australia | 2004206886 | ⤷ Start Trial | |||
| Brazil | PI0406591 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
